Arrowhead Pharmaceuticals (Germany) Performance
| HDP1 Stock | EUR 15.94 0.06 0.38% |
The firm shows a Beta (market volatility) of -0.19, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Arrowhead Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Arrowhead Pharmaceuticals is likely to outperform the market. At this point, Arrowhead Pharmaceuticals has a negative expected return of -0.37%. Please make sure to confirm Arrowhead Pharmaceuticals' total risk alpha, potential upside, kurtosis, as well as the relationship between the treynor ratio and skewness , to decide if Arrowhead Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Arrowhead Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 184.4 M | |
| Total Cashflows From Investing Activities | -5.4 M |
Arrowhead |
Arrowhead Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 2,083 in Arrowhead Pharmaceuticals on December 6, 2024 and sell it today you would lose (489.00) from holding Arrowhead Pharmaceuticals or give up 23.48% of portfolio value over 90 days. Arrowhead Pharmaceuticals is producing return of less than zero assuming 3.8625% volatility of returns over the 90 days investment horizon. Simply put, 34% of all stocks have less volatile historical return distribution than Arrowhead Pharmaceuticals, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Arrowhead Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arrowhead Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Arrowhead Pharmaceuticals, and traders can use it to determine the average amount a Arrowhead Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0961
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | HDP1 |
Estimated Market Risk
| 3.86 actual daily | 34 66% of assets are more volatile |
Expected Return
| -0.37 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Arrowhead Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Arrowhead Pharmaceuticals by adding Arrowhead Pharmaceuticals to a well-diversified portfolio.
Arrowhead Pharmaceuticals Fundamentals Growth
Arrowhead Stock prices reflect investors' perceptions of the future prospects and financial health of Arrowhead Pharmaceuticals, and Arrowhead Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Arrowhead Stock performance.
| Return On Equity | -0.4 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (0.56) % | |||
| Operating Margin | (0.57) % | |||
| Current Valuation | 2.76 B | |||
| Shares Outstanding | 108.31 M | |||
| Price To Earning | 263.63 X | |||
| Price To Book | 8.32 X | |||
| Price To Sales | 13.82 X | |||
| Revenue | 243.23 M | |||
| EBITDA | (178.51 M) | |||
| Cash And Equivalents | 218.2 M | |||
| Cash Per Share | 2.30 X | |||
| Debt To Equity | 2.40 % | |||
| Book Value Per Share | 3.55 X | |||
| Cash Flow From Operations | (136.13 M) | |||
| Earnings Per Share | (1.29) X | |||
| Total Asset | 691.94 M | |||
About Arrowhead Pharmaceuticals Performance
By analyzing Arrowhead Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Arrowhead Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Arrowhead Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Arrowhead Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California. ARROWHEAD PHARMAC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 116 people.Things to note about Arrowhead Pharmaceuticals performance evaluation
Checking the ongoing alerts about Arrowhead Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Arrowhead Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Arrowhead Pharmaceuticals generated a negative expected return over the last 90 days | |
| Arrowhead Pharmaceuticals has high historical volatility and very poor performance | |
| Arrowhead Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 243.23 M. Net Loss for the year was (176.06 M) with profit before overhead, payroll, taxes, and interest of 243.23 M. | |
| Arrowhead Pharmaceuticals has accumulated about 218.2 M in cash with (136.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.3. | |
| Roughly 69.0% of the company shares are owned by institutional investors |
- Analyzing Arrowhead Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Arrowhead Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Arrowhead Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Arrowhead Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Arrowhead Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Arrowhead Pharmaceuticals' stock. These opinions can provide insight into Arrowhead Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Arrowhead Stock analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |